Search

Your search keyword '"Smith, Ian E."' showing total 948 results

Search Constraints

Start Over You searched for: Author "Smith, Ian E." Remove constraint Author: "Smith, Ian E."
948 results on '"Smith, Ian E."'

Search Results

1. Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer

2. HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

5. Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.

6. Molecular profiling after short-term preoperative endocrine therapy to identify oestrogen receptor positive (ER+)/HER2+ early breast tumours with favourable prognosis.

7. Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer

8. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

10. Trends and Variation in Issuance of High-Cost Narcolepsy Drugs by NHS England Organisations and Regions from 2019-2022

11. Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR

12. Rapid Application Evolution and Integration Through Document Metamorphosis

14. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

15. Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

16. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

20. Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer

21. Supplementary Figure from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

23. Supplementary methods from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors

24. Supplementary Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

26. Supplementary Data from A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

28. Supplementary Figures from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors

35. Data from A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

40. Supplementary Tables from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors

48. SUPPLEMENTARY FIGURE AND TABLE LEGENDS from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors

50. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

Catalog

Books, media, physical & digital resources